Cell And Gene Therapy Market Analysis

Cell and gene therapy plays a major role in modern healthcare, as it provides concepts and techniques that can be used in gene regulation, cell-cell interactions, regenerative capacity, and remodeling.

Global cell and gene therapy market size was valued at US$ 15,580.3 Million in 2022 and is expected to witness a CAGR of 24.7% over the forecast period (2022 – 2030).

Figure 1. Global Cell and Gene Therapy Market Share (%), by Therapy Type, 2022

Increasing prevalence of cardiovascular disease is expected to propel growth of the cell and gene therapy market.

Increasing prevalence of cardiovascular disease is expected to drive growth of the global cell and gene therapy market over the forecast period. For instance, According to the World Health Organization report published in June 2021, an estimated 17.9 million people died from cardiovascular diseases in 2019, representing 32% of all global deaths, out of these deaths, 85% were due to heart attack and stroke globally. Out of the 17 million premature deaths (under the age of 70) due to non-communicable diseases in 2019, 38% were caused by cardiovascular diseases globally.

Moreover, according to the same source, on May 20, 2022, nearly 90% of COPD, Chronic obstructive pulmonary disease caused deaths globally in those under 70 years of age occur in low- and middle-income countries (LMIC) like India and Bangladesh.

Cell And Gene Therapy Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 15,580.3 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	24.7%	2030 Value Projection:	US$ 90,984.2 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Therapy Type: Cell Therapy, Stem Cells, T Cells, Dendritic Cells, NK Cells, Tumor Cells, Gene Therapy By Indication: Cardiovascular Disease, Cancer, Genetic Disorder, Infectious Disease, Neurological Disorders By Scale of Operation: In House, Outsourced
Companies covered:	Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer, Regeneron Pharmaceuticals Inc, Spark Therapeutics, Agilis Biotherapeutics, Angionetics AVROBIO, Freeline Therapeutics, Horama, MeiraGTx, Myonexus Therapeutics, Nightstar Therapeutics, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., MEDIPOST, and Bluebird Bio. Inc.
Growth Drivers:	Increasing prevalence of cardiovascular disease  Increasing prevalence of neurological disorders in North America
Restraints & Challenges:	Several development challenges such as safety and efficacy issues, lengthy procedures for conducting clinical studies, stringent regulatory framework, and high costs of cell and gene therapy

Figure 2. Global Cell and Gene Therapy Market Share (%), by Region, 2022

Increasing prevalence of neurological disorders in North America is expected to bolster the market growth over the forecast period.

Increasing prevalence of Parkinson Disease is expected to boost demand for global cell and gene therapy market over the forecast period. For instance, according to the Parkinson’s disease Foundation, as of 2022, over 10 million people are suffering from Parkinson’s disease, worldwide. The findings published by the organization demonstrated that incidence rate of Parkinson Disease increases with age and only 4% of people were diagnosed with PD before the age of 50 years. According to the same source, in 2021, the incidence rate of PD in the U.S. was as high as 60,000, annually.

 Moreover, according to a study report published by Parkinson’s disease Society of the United Kingdom in 2022, it was estimated that the rate of prevalence of Parkinson’s disease in 2017, was 1-2 people in every 100,000 aged 20-29 and 4 or 5 people in every 100,000 aged 30-39. Prevalence increased with age with the prevalence for those aged 80-84 being 1,696 per 100,000 people which is equivalent to around 1.7% of this age-group in the U.K.

Global Cell and Gene Therapy Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

The sudden outbreak of COVID-19 has bought the world to a standstill. The whole world is fighting this pandemic with increased burden on hospitals and healthcare professionals. In March 2021, according to Blood cancer U.K., a U.K.-based charity organization, conducted a virtual survey in which 47% of respondents reported that their blood cancer appointments and treatment had been impacted in some manner by the pandemic whereas 45% had not been performed due to appointment cancellations or postponement.

Global Cell and Gene Therapy Market: Key Developments

• In March 2021, The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy. Abecma is the cell-based gene therapy approved by the FDA for the treatment of multiple myeloma. Multiple myeloma is an uncommon type of blood cancer in which abnormal plasma cells build up in the bone marrow and form tumors in several bones of the body. This disease keeps the bone marrow from making enough healthy blood cells, which can result in low blood counts.
• In June 2021, CyGenica, a biotechnology company, had announced that it had raised US$1.4 million in a seed fund investment round, led by global venture capital investor SOSV, a non-governmental organization. The funding round would accelerate validation of CyGenica's proprietary technology, for safe, targeted and affordable intercellular drug delivery. The investment would accelerate the development of disruptive drug delivery technology in the advancement of therapeutics for cancer and rare diseases to improve patient's health and quality of life.

Global Cell and Gene Therapy Market Restraints

Several development challenges such as safety and efficacy issues, lengthy procedures for conducting clinical studies, stringent regulatory framework, and high costs of cell and gene therapy.

• Some of the major factors like the ideal gene delivery systems should have:
• High gene transfer efficiency
• Low toxicity to the cells
• Single cell specificity to the intended target
• The ability to simultaneously treat heterogeneous systems with many different cells

Key Players

Key players operating in the global cell and gene therapy market include Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer, Regeneron Pharmaceuticals Inc, Spark Therapeutics, Agilis Biotherapeutics, Angionetics AVROBIO, Freeline Therapeutics, Horama, MeiraGTx, Myonexus Therapeutics, Nightstar Therapeutics, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., MEDIPOST, and Bluebird Bio. Inc.